Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Mr Costs:
‘ Think about this logically, RM presents in the United States of America, the biggest presentation he has arguably ever done for Synairgen and they are only updating the website in the next few days.
Very very exciting news. I can now see why all the derampers have been out today, they knew what was happening.’
HAHAHAHAHAHAHA HAHAHAHA HAHAHAHAHA
You have nailed it.
If there was a trial planned, the CEO wouldn’t be talking about COPD. Synairgen are clutching at straws and they know they will use their remaining cash up by funding another trial.
That remaining cash is their cushty fat salaries.
Why should Marsden let go of something he has spent 19 years at?
19 years and a good few million £ in the bank for absolutely zero productivity and zero results.
He would be mad to let go of that.
The way this board works is by nourishing their own pockets. Currently they are desperately looking for free trials, to no avail. But when the time comes for them to stump up the cash to fund their own trial, the board would rather do a fund raise to dilute the shareholders existing shares even more in order to ensure continuing fat salaries for the next few more years.
There is zero incentive for Marsden to get this over the line, he has been rewarded with 300k a year and also bonus’ for 19 years of failure.
There is no incoming news.
The quicker people realise this = the quicker the delusion ends.
It doesn’t take 8 months for a biotech company to find out if it is on a platform trial. Nor does it take 8 months for a biotech company to announce a new trial.
There are small biotech companies over the world who are funding their own trials. They begin multiple new trials each year. It is extremely bizarre that in 8 months Synairgen seem incapable of updating their shareholders on any trial related news.
Remember, without a successful P3 trial this company has no product to sell, they are simply a university spin off amateur research group. As such the share price will continue to decline, reflecting that Synairgen are a university spin off research group.
The 19p’s were reached today. Expect 17p to be reached within another 6 weeks.
Releasing ACTIV2 data means sweet FA because it’s only phase 2, the only thing Synairgen have from that data is a chance that pharma will try to buy them out.
So much for Polygon accumulating, looks like they were simply lowering their average.
17/18p incoming.
Then if no trial news occurs, it’s back to the wilderness years for Synairgen. Back to the historic lows of 6p etc.
They will eventually need to do a fund raise again to pay for Marsden’s fat salary and bonus’, as well as all the other inflated staff they now have.
We could see 12p this year, followed by a fund raise next year and back down to 6p again.
Billy, if indeed there is STRIVE (which is probably 50/50 as you can not rely on rampers on this forum for information). Then it will most likely be announced when the flu/covid season starts kicking off again.
November/December.
This stock is dead without news. The company itself are unable to do a trial with the 20 or so million they have left (They are reluctant because they know without that money they can not pay their wages, thus far this company has been a cash cow at investors expense).
This is a period of news rut.
No news likely until November time, Covid likely to flare up in the winter. Price likely to continue its decline until something is announced.
Hence 15-17p price target.
Unless a new offering is announced, then SP goes under 10p.
Anything under 10p is worth a punt.
Alternatively could put 10k in at 16p and then if SP goes below 10p can average down again and hold.
With a new fund raise it keeps Marsden in his position until retirement, so there is plenty of incentive on the CEO’s behalf to do another fund raise at some stage, a cushty 300k a year wage and a very nice fat pension, phuck the thick shareholders dumb enough to search for gold.
For the first time in a while we breached lower than the 20p safety net. It looks like soon enough with zero news this stock should be neatly within the 15 to 17p range, as predicted.
The company then either have a choice:
1. Be included on a government platform trial for their candidate drug SNG001. Thus far the CEO has said they are working tirelessly and ‘with haste’ to find a new sponsored trial, albeit zero news on this front in the last 8 months.
2. Fund their own trial for SNG001 in either Covid or COPD. In which case they will need a fund raise, thus diluting the number of issues shares and the SP will fall to under 10p.
3. Do nothing, leach of shareholders money and then do another fund raise.
Zero positive news this far, makes one wonder that winter might possibly bring some covid related news.
15-17p target price at the moment. 10p target price with a fund raise.
Under 15p it’s worth a long term speculative punt.
Thus far Marsden the Synairgen CEO has failed to speak up about being initiated in to a platform trial. Synairgen are now approaching seven months after their horrendous P3 result.
I am personally predicting no news until at least October/November time which allows the price to fall back to the 15-18p price target I set last month.
However, should Marsden fail to get Synairgen enrolled on to a new platform trial, a new fund raise and share dilution will be the only way to continue research.
It’s safe to assume that with zero communication in many months from the CEO or team that there is no upcoming platform trial planned for September which allows the price to decline through until October.
In the event of a Synairgen fund raise what price do we think this company will fall to?
Let’s assume 18p or 19p SP to be generous in October.
Therefore with a new fund raise, perhaps 15p?
I concur that at 12-15p this company would certainly be a good long term speculative punt. Plenty of room for the current share price to fall, given the lack of news and direction of the CEO, but at 12p it’s definitely worth the punt, even if it does generate publicity, elevating the SP, for it only to fall flat on its face again. 12p buy in can deliver a return of multiples.
Congrats are in order, Synairgen has managed to stay a smidge above 20p.
But let’s wait to see what 3 more months of zero news (other than RM working at ‘haste’) does to the SP.
I maintain the sensible target price of 15p, with 12p the lower end. Then if RM fails to substantiate another trial (highly likely outcome), a fund raise will be needed before the company collapses, after another fund raise, 5-10p.
Enjoy your beautiful bank holiday, as I will do from Marbella :)
Ta ta for now ;)
I remember we used to play this game, back when the price was £1.77 and we thought ACTIV 2 news was going to drop and the share would burst up 75%
When ACTIV news came through it went up around 20% but was still fun. We had the prospect of a drug that would get approved if the phase 3 trial was a success.
So anyway, guess the price when the bell rings on Friday.
I say 20.77p
Everyone, look up ‘STRIVE’. You can see the NIH had a series of trials for influenza called ‘STRIVE’ many years back.
This is the new thing being ramped on this board.
Utterly pathetic.
The fact that people on this board frequent it every day for the last two years with optimistic posts, YET SYNAIRGEN HAVE DONE F11k ALL IN 20 YEARS, just illustrates the sheer madness and delusion on this forum.
Quick, you’d better be positive about Synairgen.
Why? It’s a sh11t company with no future.
Speculative gamble at best. Wait for the price to drop to 15p per share before buying in.
The same morons will be on here when the price is 12/15p chanting ‘Synairgen Synairgen Synairgen’ ‘not long now before the US government includes us on a trial, don’t sell your cheap shares’.
To the rampers, seriously? You’re seriously ramping this utter garbage still?
gunto, what will STRIVE do? Another trial and 18 months of waiting for another phase 2 trial result, doesn’t bring this product closer to market.
It’s completely pitiful.
The SP of this incredible company is now 22p and will fall to below 15p with the incoming recession.
Rampers on here have been saying this share is about to explode any day soon. They’ve had six whole months for it to do something. But the company can’t even mention a trial in six months.
What will happen in another six months?
Will ‘STRIVE’ suddenly boost Synairgen up 1000%?
Or will ‘STRIVE’ be a figment of rampers and delusional Synairgen fanatics minds?
Truly pitiful. Advice stays the same, wait until 15p price target and then buy as a gamble.
Only 30% less and we get to the 15p price target I have set.
With absolutely nothing in the pipeline, no trials, no communication, no direction and a very poor team of staff at Synairgen who have been ‘working at haste’ for the last six months and unable to a achieve anything, it stands to reason that this share will fall a further 30%
As we head deeper in to recession, all stocks will continue to decline over the coming year. Therefore I maintain the target price of 15p. Buy in for a speculative gamble at 10-15p per share.
If there needs to be a fund raise to generate cash for Synairgen to run their own trial (heaven help them if they do try to run another trial again, the last one was horrendous), then that will dilute the shares further.
With fund raise expect SP to go 8-10p, without fund raise expect SP to go to 10-15p.
What use is a university spin off research company that hasn’t got a product to market and can’t get a product to market in two decades, despite them having a cure for a pandemic that had trillions spent on it.
No chance, this company is a turkey, a dud, all the rampers on here keep on talking about the potential of interferons but who cares? They’ve had potential for thirty years and Synairgen can’t do anything.
I wonder, what have all these new hirings and the CEO been doing every day for the last six months when they go in to the office? They have been ‘working at haste’ to get on to a free government sponsored trial for covid.
It’s pititful.
Speculative long term gamble when the price reaches below 15p. Synairgen totally blew their chance.
Not a bad day for Synairgen, we’ve seen much worse before.
I maintain my 15p price target.
There is no news impending with this company. Major shareholders know this, hence they are selling their stakes now. The CEO has achieved nothing in twenty years. When the company blew their single biggest chance that they raised £80m for, that signalled the end of this company.
15p price target, potentially as low as 9/10p per share.
Once it reaches this, it can be a long term speculative gamble.
There are no trials (even if there were, the drug wouldn’t be approved for over 18 months), nor are Synairgen planning any trials themselves as they don’t have enough money. Would you even trust Synairgen to run their own phase 3 trial, after the debacle of the last one?
However the team are ‘working at haste’ over the last six months to be included in a free government trial.
Pitiful.
Avoid for now. Invest as a gamble when the price goes below 15p.
When the price was £2, we heard the screaming of ‘They’re trying to take your cheap shares’ (in a camp loud Terry Christian voice.
Now the price is 24p and falling, we still hear the screams of ‘They’re trying to take your cheap shares’.
Absolutely pitiful. If anyone wanted these shares they could have bought them for 10p after the dreadful phase 3 failure that took 2 years to screw up.
They still have £25m in the bank, if they were serious about taking the drug to market they would design a simple and effective phase 3 trial with the cash that they already have.
Twenty years on from taking over the management, Marsden is begging for the interferon to be trialled by governments. The same as he was a decade ago.
Covid is going to become prominent again this winter time and there will be loads of cases within the UK hospitals, easily enough to gather 1000 patients for a clinical trial within the space of a few months.
This company is a dud, there are other biotech companies out there which have legitimate drugs in trial right now. There is no reason whatsoever to invest in Synairgen at these price levels.
In 18 months time the company will be worried about exhausting their cash runway. Once this happens they will need to do a fund raise again, this will slash the SP down a further 30/40%.
Wait until 2024 and then buy in at under 15p for a long term speculative punt. But be aware that you might have to wait decades to get that great return that you would expect with a biotech company.
As per the title.
Advice is to leave this stock.
If you want the speculative punt, 15p is a fair buy in price.
The company was ‘working at haste’ to be included on new platform trials. Thus far, zero news in six months.
There is enough cash runway to last 24 months, then a new fund raise is needed. Price will fall to 10p or less when fund raise is needed. This has been the process for the last two decades with this company, what is the magic bullet which will cause a difference this time?
They flumped their only chance at being relevant.
Not a single person, scientist or manager, with all their experience at Synairgen knew that giving steroids alongside interferon would yield a lesser response and ruin their once in a lifetime trial.
Price heading to 15p.
For those new to Synairgen, we ask the question, is it a good investment?
The company itself was able to capitalise from the pandemic with its inhaled interferon treatment against covid. Initially targeting COPD and other respiratory illnesses however failed to be bought out by Astra Zeneca when COPD trial results were inconclusive.
The company then had a great chance at releasing their interferon inhaled treatment during the pandemic. After a successful phase 2 trial the share price rose by 500%. Synairgen found itself amongst the cutting edge of potential therapeutics for Covid19, it was included on the ACTIV trials started with operation warp speed to find new therapeutics designed to treat Covid 19.
The company itself made a fund raise and gained £80 million which was to fund it phase 3 trial. 16 months after the fund raise, the results of their phase 3 trial were released. Unfortunately the phase 3 trial was exceptionally poorly planned and left the share price 85% down, where it remains today.
The CEO of the company insists that he and the team are desperately scrambling to get their drug included on platform trials run by governments, however it has now been six whole months since the disastrous trial result and as of yet there is no news on any new trial.
Covid19 has mutated in to a less harmful virus, however persists to be a problem and could flare up badly during the winter months.
So is there potential with the company?
Like all investments, it’s a gamble. But with Synairgen, as they currently have no product for sale, they do not make any profits. They have a strong enough cash runway to last 24 months, however not enough to fund another trial. The company has said it is desperately looking for new trials to join, however the need to develop new covid therapeutics has decreased due to the giant pharma companies already releasing their drugs which are now available for governments to purchase. Unless they are able to join a government sponsored trial, they will need to do a fund raise for themselves, in which case the shares will be diluted further and the share price will fall accordingly.
Unfortunately the comms from this team is terrible. Many investors who were hopeful of a successful phase 3 outcome were in dismay by the lack of haste or communication by Synairgen to their shareholders.
Due to the diminished need to create new drugs to combat Covid19 and also the increasing likelihood of not getting on to a free sponsored trial it looks like Synairgen are going to be in the wilderness for quite some time. Consensus appears that the current cash runway will be depleted and the need for Covid19 drugs is not great enough to finance heavily sponsored government trials.
The consensus therefore should be to avoid this company, or wait until the share price falls to below 15p and then make an investment as a speculative future gamble.
There are other small upcoming biotech companies that are more worthy
There is thirty years of data to show this might be the case.
But without a product approved, without a trial, without a joint venture to get a trial and then approval, Synairgen are utterly useless and pointless.
Hence why the SP is 20-30p.
If the board don’t manage to get a JV or on a platform trial then a fund raise is needed, in which case trading price goes 10-20p.
Rest assured, Marsden et co are ‘working at haste’.
Marsden ‘working at haste’ could be anything from 12 months to 12 years.
Best.
Drew
I lost half my money here. Still, 40 grand.But managed to get 40k back through trading.Such a pity that this company and the CEO/Staff are a bunch of total amateur monkeys that couldn’t organise a party in a brewery.The demand for Interferon beta is so high. Arguably higher than ever now.But because the staff and management at Synairgen are so incompetent, they ruined the trial for the golden drug that would have saved hundreds of thousand of lives.Pfizer’s Paxlovid is being pulled, not working properly.Wait till winter time, covid will strike again. But sadly, thanks to Marsden et co ruining everything, there will be NO interferon to save anyone.https://www.fiercepharma.com/pharma/pfizer-stops-paxlovid-work-less-vulnerable-covid-19-patients-after-no-benefit-symptom-reliefThis company has a lot of rampers on this board. Almost like a die hard contingent of loyal fans, even after 20 years of failure. They will ramp up this drug, which is good because this drug does have so much potential. The problem is that the company who are trying to bring this drug to market simply don’t have a clue how to run a trial properly or with enough haste.Invest in this company as a highly speculative gamble.They have a wonder drug. The problem is, they are utterly useless at getting this wonder drug approved.Until it’s approved, they will eventually run out of money and need to do a fund raise.Put it this way, they have a wonder drug, but the CEO hasn’t been able to get it approved in twenty years of working for the company. That’s the type of amateurs you’re dealing with, when you invest your money in Synairgen. You are quite literally giving your money to a monkey, in the hope that it will solve a Rubix cube.
My last post on here, since I vacated from this stock two weeks ago.
I hear cheers of ‘hooray’ and the incoming footsteps of those sad little people desperate to have a final dig because this forum and this dreadful company is everything in their life. Their beloved Synairgen and Marsden have completely flopped yet again.
I sold out two weeks ago.
Made no secret that I was trading this share, (I was even telling people when to buy and when to sell, helping others make profit) that’s all this share is good for. The rise to 45p meant that I could escape this dreadful company with only a 40% loss. Others were able to do so as well, if they saw sense.
To all the holders who have been badly stung by Marsden, this company and the cult of fanatical rampers I bid you adios from sunny Chelmsford, may you see more favourable days in other ventures that you pursue. My advice would be to trade this share as much as you can, it is going absolutely nowhere in the short term, after going nowhere in the last twenty years.
The board just don’t have a clue how to commercialise this drug, they’re in way above their amateur level and need help from real pharma companies if this drug is going to come to market.
I’m sure the rampers will be here for many years to come, luring in potential investors, talking about the science behind interferon. The science has been around for the last three decades, yet Synairgen and their CEO Marsden have been unable to bring interferon to commercialisation, despite 19 years of trying (what does that tell you about them?).
Always look on the bright side of life, even billionaires got it wrong when it came to the ramping of Theranos.
Enjoy a happy and sunny summer.
Drew
Here’s a hint:
Read in between the lines :D : D
Why am I saying that it’s last chance saloon for Synairgen?
Who are propping up the SP right now?
Who is trading this stock right now (with the exact same trading pattern as before).
None of you have the foggiest clue what I’m talking about do you? You’re all completely oblivious because none of you work in the city. It’s actually quite funny.
Like I wrote, I can lead a horse to water. But can’t force it to drink :D
Good luck to you all.
Seaboy, on the contrary, I know exactly what I’m invested in.
I even helped others over the last three weeks to make money.
All I see on this forum is links about science, or people trying to do detective work, when thus far this company has been a total dud.
So I told people exactly when to buy and when to sell.
I made 30% in 3 weeks.
What’s hilarious is if people had actually listened, they would have made the money too.
No one on this forum actually stops and thinks ‘hmm, how come andybe4 got this right?’
I told everyone that it’s the same traders and the same trading pattern.
Oh well, you can flog a dead horse to water, but ya can’t force it to drink.
Last chance saloon for Synairgen tomorrow, or the whole thing goes up in flames.